Disclosed herein are cationic liposomes suitable for specific delivery of immunomodulating agents to monocytes and dendritic cells. The cationic liposomes comprise phospholipids, cholesterol, cationic lipids, PEG and at least one active ingredient and have a zeta potential in the range of 13-25 mV. Further disclosed are uses of such cationic liposomes in various pharmaceutical applications.
|IPC||A61K31/522; A61K39/39; A61K47/02; A61K47/69; A61K9/127; A61P35/00|
|Country||International Bureau of the World Intellectual Property Organization (WIPO)|
|Publication status||Published - 2019|